The FOCUSED study: FMT in OCD patients

Summary

This study will explore the safety and efficacy of Fecal Microbiota Transplantation (FMT) in individuals with OCD. Participants will be given FMT capsules and asked to provide stool, urine, saliva, and blood samples, and will be followed on a weekly basis for a period of 4 months.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 18 to 65

Inclusion criteria:

1- Male and female participants aged 18-65 years.
2- Have a confirmed diagnosis of OCD.
3- Be on a stable medication treatment for OCD and experiencing symptoms for at least 12 weeks.
4- Must score 16 points or higher on the OCD diagnostic survey.
5- Able to communicate and fill questionnaires in English.
6- Able to come to the Foothills campus for each of the study visits.

Exclusion criteria:

1- Recent (last 3 months) substance use disorder, excluding cannabis.
2- Moderate or severe cannabis use in the last 3 months.
3- Active eating disorders.
4- Schizophrenia or similar mental health conditions.
5- High risk of suicide (moderate risk may be considered).
6- Participants with chronic gastrointestinal issues.
7- Past gut problems or surgeries that could block the intestines.
8- Conditions that weaken the immune system.
9- Participants using regular anti-inflammatory drugs, iron supplements or pre- and pro-biotics in the last 3 months.
10- Trouble swallowing or less than two bowel movements per week.
11- Pregnant, planning pregnancy or breastfeeding females

Participate

Fill out the following form if you want to participate in this research

Method of contact

UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is committed to ensuring the privacy of all students, staff, and community members. Your personal information is being collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used and disclosed for the purposes outlined in UCalgary’s Notice of Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s Privacy Management Program. Your personal information may be input into automated systems to generate content or make decisions, recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection, use, or disclosure of your personal information, please contact accessandprivacy@ucalgary.ca.

Additional information

Contact information

asem.bala@ucalgary.ca

Principal investigator:

Valerie Taylor

Clinical trial:

Yes

REB-ID:

REB22-1179